FRANKFURT (Reuters) – Canada on Wednesday secured supplies of an experimental COVID-19 vaccine developed by Pfizer and German biotech firm BioNTech for delivery in 2021 if the compound wins regulatory approval.
Financial details of the agreement were not disclosed, Pfizer and BioNTech said in a joint statement, but added that the terms were based on the timing of delivery and the volume of doses.
(Reporting by Ludwig Burger. Editing by Jane Merriman)
